Skip to main content


Volume 737: debated on Monday 18 September 2023

NICE Enhertu Cancer Treatment

8.58 pm

Further to the similar petition that received over 166,000 signatures, I formerly present this petition on behalf of my constituent, Elaine Lynch. It calls on the National Institute for Health Care and Excellence to authorise the use of the drug Enhertu for NHS cancer treatment among patients with the HER2 mutation, given that the drug currently holds approval exclusively for breast cancer treatment.

The petition states:

The petition of Elaine Lynch,

The petitioner declares that the National Institute for Health Care and Excellence (NICE), should take steps to approve the further use of Enhertu in NHS cancer treatments in patients that have the HER2 mutation; notes that NICE has currently only approved the use of Enhertu in the treatment of breast cancer; further notes that Enhertu has been approved in the United States for patients with the HER2 mutation.

And the petitioners remain, etc.